Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 5 481-485, Copyright © 1993 by American Association for Cancer Research

ARTICLES

Lung cancer, race, and a CYP1A1 genetic polymorphism

PG Shields, NE Caporaso, RT Falk, H Sugimura, GE Trivers, BF Trump, RN Hoover, A Weston and CC Harris
Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892.

The assessment of human cancer risk using molecular epidemiological techniques involves determining the relative contributions of inherited and acquired genetic predispositions, in the context of environmental exposures. Recently described genetic polymorphisms for CYP1A1, a gene involved in the metabolic activation of polycyclic aromatic hydrocarbons, have been associated with lung cancer risk in a Japanese population. We report herein findings from a United States case-control study of lung cancer (56 cases; 48 controls). The polymerase chain reaction followed by an Msp1 restriction enzyme digestion was used to analyze constitutive DNA but no association between the restriction fragment length polymorphism and lung cancer risk was found (odds ratio, 0.7; 95% confidence interval, = 0.3-1.6). Analysis of genotype by cumulative smoking status did not reveal an elevated risk among lesser or greater smokers. The presence of the CYP1A1 Msp1 site-present allele, which was previously found to be associated with Japanese lung cancer risk, was statistically increased in African compared to Caucasian Americans (odds ratio, 2.9; 95% confidence interval, 1.2-2.7). When stratified by race, however, no association between case status and the polymorphism was observed, but the small number of study subjects within each racial group limited the statistical power. Larger studies are required to evaluate the risk of the CYP1A1 Msp1 polymorphism in African Americans.

This article has been cited by other articles:

				A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF]

				D. A. Freedman Graphical Models for Causation, and the Identification Problem Eval Rev, August 1, 2004; 28(4): 267 - 293. [Abstract] [PDF]

				S. Garte, L. Gaspari, A.-K. Alexandrie, C. Ambrosone, H. Autrup, J. L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, et al. Metabolic Gene Polymorphism Frequencies in Control Populations Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1239 - 1248. [Abstract] [Full Text] [PDF]

				G. B. J. Smith, P. A. Harper, J. M. Y. Wong, M. S. M. Lam, K. R. Reid, D. Petsikas, and T. E. Massey Human Lung Microsomal Cytochrome P4501A1 (CYP1A1) Activities: Impact of Smoking Status and CYP1A1, Aryl Hydrocarbon Receptor, and Glutathione S-Transferase M1 Genetic Polymorphisms Cancer Epidemiol. Biomarkers Prev., August 1, 2001; 10(8): 839 - 853. [Abstract] [Full Text] [PDF]

				S. D. Spivack, G. J. Hurteau, A. A. Reilly, K. M. Aldous, X. Ding, and L. S. Kaminsky CYP1B1 Expression in Human Lung Drug Metab. Dispos., June 1, 2001; 29(6): 916 - 922. [Abstract] [Full Text]

				N. Song, W. Tan, D. Xing, and D. Lin CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China Carcinogenesis, January 1, 2001; 22(1): 11 - 16. [Abstract] [Full Text] [PDF]

				H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]

				M. Rojas, I. Cascorbi, K. Alexandrov, E. Kriek, G. Auburtin, L. Mayer, A. Kopp-Schneider, I. Roots, and H. Bartsch Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism Carcinogenesis, January 1, 2000; 21(1): 35 - 41. [Abstract] [Full Text] [PDF]

				K. B. Moysich, P. G. Shields, J. L. Freudenheim, E. F. Schisterman, J. E. Vena, P. Kostyniak, H. Greizerstein, J. R. Marshall, S. Graham, and C. B. Ambrosone Polychlorinated Biphenyls, Cytochrome P4501A1 Polymorphism, and Postmenopausal Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 1999; 8(1): 41 - 44. [Abstract] [Full Text]